Key result
Combining an enhanced tissue renin-angiotensin system with streptozotocin-induced hyperglycaemia in Ren-2 rats led to diastolic dysfunction and adverse remodeling (p<0.01 vs non-diabetic).
Why the study?
Does streptozotocin-induced diabetes cause diastolic dysfunction and adverse remodeling in (mRen-2)27 rats with an enhanced tissue renin-angiotensin system?
Does streptozotocin-induced diabetes cause diastolic dysfunction and adverse remodeling in (mRen-2)27 rats with an enhanced tissue renin-angiotensin system?
In a rodent model, the combination of an enhanced tissue renin-angiotensin system and hyperglycemia leads to the development of diabetic cardiomyopathy characterized by diastolic dysfunction and adverse remodeling.
Answers are grounded in this paper and cite their sources.
May inform preclinical diabetic cardiomyopathy models; leaves open human HFpEF relevance.
OBJECTIVE: Diabetic cardiomyopathy is an increasingly recognized cause of cardiac failure despite preserved left ventricular systolic function. Given the over-expression of angiotensin II in human diabetic cardiomyopathy, we hypothesized that combining hyperglycaemia with an enhanced tissue renin-angiotensin system would lead to the development of diastolic dysfunction with adverse remodeling in a rodent model. METHODS: Homozygous (mRen-2)27 rats and non-transgenic Sprague Dawley (SD) rats were randomized to receive streptozotocin (diabetic) or vehicle (non-diabetic) and followed for 6 weeks. Prior to tissue collection, animals underwent pressure-volume loop acquisition. RESULTS: Diabetic Ren-2 rats developed impairment of both active and passive phases of diastole, accompanied by reductions in SERCA-2a ATPase and phospholamban along with activation of the fetal gene program. Structural features of diabetic cardiomyopathy in the Ren-2 rat included interstitial fibrosis, cardiac myocyte hypertrophy and apoptosis in conjunction with increased activity of transforming growth factor-beta (p<0.01 compared with non-diabetic Ren-2 rats for all parameters). No significant functional or structural derangements were observed in non-transgenic, SD diabetic rats. CONCLUSION: These findings indicate that the combination of enhanced tissue renin-angiotensin system and hyperglycaemia lead to the development of diabetic cardiomyopathy. Fibrosis, and myocyte hypertrophy, a prominent feature of this model, may be a consequence of activation of the pro-sclerotic cytokine, transforming growth factor-beta, by the diabetic state.
No takes yet. Share an insight, caveat, or question.
Connelly et al. (2007) studied Diabetic cardiomyopathy. Streptozotocin (diabetic) vs. Vehicle (non-diabetic) was evaluated on Diastolic dysfunction and structural features (interstitial fibrosis, cardiac myocyte hypertrophy, apoptosis, TGF-beta activity) (p=<0.01). Combining an enhanced tissue renin-angiotensin system with streptozotocin-induced hyperglycaemia in Ren-2 rats led to diastolic dysfunction and adverse remodeling (p<0.01 vs non-diabetic).
Synapse has enriched 10 related papers. Consider them for comparative context: